

## AGENDA

### 10:30 – 10:45 **Welcome and Update on Activities**

#### **Welcome Remarks**

David Lewinsohn, Chair, WGNV

#### **Update on Activities**

Jennifer Woolley, Secretariat, WGNV

Carly Young, Co-Chair, WGNV Early Career Researcher Network; WGNV Core Group; University of Cape Town

Shaun Palmer, Coordinator, TB Vaccine Advocacy Roadmap; WGNV Core Group; IAVI

### 10:45 – 11:10 **Key Outcomes from the 7<sup>th</sup> Global Forum on TB Vaccines**

#### **General Overview & Early Stage/Preclinical Research**

David Lewinsohn, 7GF Co-Chair; WGNV Chair; Oregon Health & Science University

#### **Clinical Research**

Ann Ginsberg, WGNV Core Group; 7GF Organizing Committee; Gates Foundation

#### **Implementation and Public Health Impact**

Richard White, WGNV Core Group; 7GF Organizing Committee; London School of Hygiene & Tropical Medicine

#### **Community Engagement**

Shaun Palmer; WGNV Core Group; 7GF Community Engagement Committee; IAVI

### 11:10 – 11:50 **Updates on the M72/AS01E and MTBVAC Vaccine Candidates**

#### **TB Vaccine Clinical Pipeline Overview**

Ann Ginsberg, Gates Foundation

#### **MTBVAC**

Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town

#### **M72/AS01E**

Alemnew Dagneu, Bill & Melinda Gates Medical Research Institute

### 11:50 – 12:25 **Implementation and Community Engagement**

#### **Implementation of New TB Vaccines**

Birgitte Giersing, WHO

#### **Community Engagement in TB Vaccine Research, Development, and Implementation**

Peter Ngo'la Owiti, WGNV Core Group; Gavi CSO Steering Committee; Affected Community Delegation to Stop TB Partnership

### 12:25 – 12:30 **Closing**

#### **Closing Remarks**

David Lewinsohn, Chair, WGNV